• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    Co-clinical mouse/human trials aim to speed up drug approvals

    The many breakthroughs in understanding the pathways involved in leukemia have delivered a double-edged sword: hundreds of new drugs await testing but an insufficient patient pool exists to conduct clinical testing in a timely way

    Functional genomics yields drivers, mutations, and pathways in leukemia

    The study of genes, mutations, and collective pathways contributing to leukemia is a cornerstone of the DF/HCC Leukemia Program, led by Thomas Look, MD (DFCI) and co-leaders David Scadden, MD (MGH), Pier Paolo Pandolfi, MD, PhD (BIDMC), and Scott Armstrong, MD, PhD (CHB)

    Twenty-four new members join DF/HCC

    Twenty-four individuals have recently joined DF/HCC

    BWH names Nabel next president
    Szostak wins Nobel Prize
    Fall eNews

    The Fall edition of eNews, DF/HCC's quarterly newsletter, has just been published

    Bench to bedside translational science doubling myeloma survival

    Ive been at this for 30 years and the last five years have been truly remarkable, says Kenneth Anderson, MD (DFCI)

Displaying results 106 to 112 out of 223